“
“Symbiosis, a range of intimate relationships Plants, animals, and diverse microbes engage in a wide range of interactions that can be characterized as symbiotic, that is, the living together of unlike organisms [1–5]. The Plant-Associated Microbe Gene Ontology (PAMGO) Consortium

[6] has been developing an extensive set of Gene Ontology (GO) [7] terms that describe processes and structures underlying symbiotic interactions between organisms, ranging from mutualists through parasites [8]. This mini-review focuses on the selleck screening library nutrient acquisition BI 2536 supplier strategies of a range of symbiotic organisms. Here “”nutrient”" is defined as any chemical substance required for metabolism or development. GO terms that describe gene products related to nutrient exchange during symbiosis are discussed along with examples of symbioses involving bacteria, protozoans, fungi, animals, oomycetes, algae, and plants. The Gene Ontology The GO is a controlled vocabulary consisting of GO terms that describe gene product attributes in any organism [9]. GO terms are arranged as directed acyclic graphs (DAGs) within three ontologies, “”GO: 0005575 cellular

component”", “”GO: 0008150 biological process”", and “”GO: 0003674 molecular function”". DAGs differ from hierarchies in that each term (child) may be related to more than one less specific term (parent). Three specific relationships among parent and child terms within a DAG are currently recognized by the GO: “”is_a”", “”part_of”", and “”regulates”". For example, “”GO: 0052010 catabolism by symbiont of host cell wall Selleckchem EX 527 cellulose”" Interleukin-2 receptor is a type of “”GO: 0052009 disassembly by symbiont of host cell wall”", and thus these terms would be

connected by the “”is_a”" relationship (for more information on term-term relationships and ontology structure, see [9]). The concept of symbiosis in the Gene Ontology In the GO, the concept of symbiosis is represented by the term “”GO: 0044403 symbiosis, encompassing mutualism through parasitism”", which is defined as: “”An interaction between two organisms living together in more or less intimate association. The term host is usually used for the larger (macro) of the two members of a symbiosis. The smaller (micro) member is called the symbiont organism”" [10]. The various forms of symbiosis include parasitism, in which the association is disadvantageous or destructive to the host organism; mutualism, in which the association is advantageous to both; and commensalism, in which the symbiont benefits while the host is not affected [8]. However, mutualism, parasitism, and commensalism are not discrete categories of interactions but rather a continuum. In fact, the nature of a symbiotic interaction may vary due to developmental changes in the host or symbiont, changes in the biotic or abiotic environment, or variation in host genotype [11]. Correspondingly, the exchange of nutrients between symbiotic partners may be context dependent and may be bidirectional or heavily unidirectional.

Qual Saf Health Care 16:230–234CrossRefPubMed 140. Cusimano MD, Kwok J, Spadafora K (2008) Effectiveness of multifaceted fall-prevention programs for the elderly in residential care. Inj Prev 14:113–122CrossRefPubMed

141. Oliver D, Connelly JB, Victor CR, Shaw FE, Whitehead A, Genc Y, Vanoli A, Martin FC, Gosney MA (2007) Strategies to prevent falls and fractures in hospitals and care homes and effect of cognitive impairment: systematic review and meta-analyses. BMJ 334:82CrossRefPubMed 142. Kerse N, Butler M, Robinson E, Todd M (2004) Fall prevention in residential care: a MEK inhibition cluster, randomized, controlled trial. J Am Geriatr Soc 52:524–531CrossRefPubMed 143. Kaptoge S, Benevolenskaya LI, Bhalla AK et al (2005) Low BMD is less predictive than reported falls for future limb fractures in women across Europe: results from the European Prospective Osteoporosis Study. MAPK inhibitor Bone 36:387–398CrossRefPubMed 144. Lauritzen JB, Petersen MM, Lund B (1993) Effect of external hip protectors on hip fractures. Lancet 341:11–13CrossRefPubMed 145. Jantti PO, Aho HJ, Maki-Jokela PL, Heikinheimo RJ (1998) Hip protectors and hip fractures. Age Ageing

27:758–759CrossRefPubMed 146. Ekman A, Mallmin H, Michaelsson K, Ljunghall S (1997) External hip protectors to prevent osteoporotic hip fractures. Lancet 350:563–564CrossRefPubMed 147. Chan DK, Hillier G, Coore M, Cooke R, Monk R, Mills J, Hung

WT (2000) Effectiveness and acceptability of a newly designed hip protector: a pilot study. Arch Gerontol Geriatr 30:25–34CrossRefPubMed 148. Kannus P, Parkkari J, Niemi S, Pasanen ZD1839 ic50 M, Palvanen M, Jarvinen M, Vuori I (2000) Prevention of hip fracture in elderly people with use of a hip protector. N Engl J Med 343:1506–1513CrossRefPubMed 149. Cameron ID, Venman J, Kurrle SE, Lockwood K, Birks C, Cumming RG, Quine S, Bashford G (2001) Hip protectors in aged-care facilities: a randomized trial of use by individual higher-risk residents. Age Ageing 30:477–481CrossRefPubMed 150. Harada A, Mizuno M, Takemura M, Tokuda H, Okuizumi H, Niino N (2001) Hip fracture prevention trial using hip protectors in Japanese nursing homes. Osteoporos Int 12:215–221CrossRefPubMed 151. Hubacher M, Wettstein A (2001) Acceptance of hip protectors for hip fracture prevention in nursing homes. Osteoporos Int 12:794–799CrossRefPubMed 152. Meyer G, Warnke A, Bender R, Muhlhauser I (2003) Effect on hip fractures of increased use of hip protectors in nursing homes: cluster randomised controlled trial. BMJ 326:76CrossRefPubMed 153. van Brigatinib Schoor NM, Smit JH, Twisk JW, Bouter LM, Lips P (2003) Prevention of hip fractures by external hip protectors: a randomized controlled trial. JAMA 289:1957–1962CrossRefPubMed 154.

Despite its recent arrival on the market of anti-infective

agents, DAP-resistant mutants have already been reported [9–12]. To prevent the occurrence of resistant mutants (especially in the presence of foreign bodies) [13–16] and to limit the increase in staphylococcal minimum inhibitory concentration (MIC) [17, 18], some authors [19, 20] suggest increasing the daily dose of DAP. Clinical experience with a dose >6 mg/kg is limited, but data reported to date suggest that DAP is safe and well-tolerated [20–22]. In this report, we present our center’s experience with high-dose DAP for empirical treatment of PVGI during the very crucial post-operative period, and as treatment adapted to microbiological results. Methods The present study was retrospectively conducted from January VX809 2008 to December 2010 and included all patients treated with DAP for PVGI at our regional referral centers for these infections (University Hospital of Lille, Lille, France and Dron Hospital, Tourcoing, France). The objective of this study was to evaluate the safety of DAP at daily dosages >8 mg/kg in patients with PVGI. This study was approved by the institutional review boards

of Dron Hospital and the University Hospital of Lille. All patients included in this study were informed and gave their consent. As in our previous studies [3], as there is no standard definition XL184 manufacturer for diagnosis of definite or suspected PVGI, we used criteria proposed by FitzGerald et al. [1]. A patient was considered as suffering Sulfite dehydrogenase from clear-cut PVGI if at least two of the following three criteria were present: (a) positive bacterial culture of intraoperative

specimens or blood samples (for potentially contaminant bacteria, such as coagulase-negative staphylococci, Propionibacterium acnes, or corynebacteria, at least two intraoperative specimens or blood samples or at least one intraoperative specimen and one blood culture were required); (b) clinical signs of infection in the area of the prosthesis; (c) biological or other radiological signs of infection (perigraft air or fluid persisting for more than 8 weeks post-operatively; abscess). Each case of definite infection was classified as early-onset infection when occurring within 4 months after surgery or as late-onset infection when occurring more than 4 months after surgery. PVGI or stent infection was suspected when bacteremia involving a site other than the surgical site occurred in the early post-operative period (within 4 weeks of graft or stent implantation) [23, 24]. PVGI was documented only by intraoperative or blood samples. Superficial samples were excluded. Multiple intraoperative samples were RG7420 cell line cultured on blood agar plates with standard aerobic and anaerobic methods. Antibiotic susceptibility patterns were interpreted in accordance with recommendations of the “Comité de l’Antibiogramme de la Société Française de Microbiologie” [25].

What I saw was different from all I had seen in my own country, in the US and in Australia. After the Soviet Union, Japan was another different world. I had some papers with Kazuo IWP-2 ic50 Shibata and young Japanese collegues (Inoue et al. 1978; Kobayashi et al. 1979a, b). Fig. 4 Kazuo

Shibata with Secretary Asayo Suzuki in 1965, SAR302503 clinical trial courtesy Asayo Iino, Tokyo, formerly Asayo Suzuki Kazuo has my gratitude and my great respect for his tolerance of the foreigner. I had been slow to understand him. When I left, I was, possibly, still a democrat, but subsequent experiences in my own country made me adopt much of what I had learnt in Japan. I had understood that loneliness is often a price to be paid for success. As another result

of my Japanese sabbatical, Yoshichika Kobayashi and Tetsuro Mimura came as postdocs to my laboratories in Düsseldorf and later to Würzburg. Kozi Asada came as Humboldt-prize winner. All of the Japanese collegues I had contact with were dedicated scientists, possessed by the Samurai spirit (see e.g., Mimura et al. 1990; Kobayashi and Heber 1995; Asada et al. 1993). They were followed by Chinese postdocs (see e.g., Ye and Heber 1984; Yin et al. 1990; Wu et al. 1991). University STA-9090 cost of Würzburg In 1978, the possibility arose to make a change once again. I received an offer to go to Würzburg as head of the chair of Botany I of the University. One hundred years earlier, Professor Julius von click here Sachs had established plant physiology there as an internationally accepted field of botanical research. Otto Lange, which whom I had visited the Soviet Union in 1962, headed the chair of Botany II. He had become a renowned ecologist (Fig. 5). The possibility of co-operation with him influenced my decision. I accepted and left the Rhineland for Frankonia in the North of

Bavaria. At the University of Würzburg I remained in a position of C4-Professor and, later, as speaker of a Sonderforschungsbereich (SFB) in which several institutes of biology and chemistry combined their research efforts until I retired officially in 1996. Intermittently, I managed to escape for a time when extended professorial and administrative duties of a large chair threatened to weigh me down. David Walker, by then head of the Robert Hill Institute of the University of Sheffield (Fig. 6), had arranged a Fellowship of the Royal Society which gave me the opportunity to go to Sheffield when life in Würzburg became intolerable. There, I could engage in experimentation. An alternative possibility for escape was provided by Roland Douce and Richard Bligny at the University of Grenoble in France. Work in the French alps led to several papers (Bligny et al. 1997 and other papers). The French university possessed a well-equipped alpine ecological station at the Col du Lautaret in the Alps which I could visit for experimental work on mountain plants as often as I wished. Fig.

Chemistry & Biology 2004,11(3):407–416.CrossRef 24. Wetli HA, Buckett PD, Wessling-Resnick M: Small-Molecule Screening Identifies the Selanazal Drug Ebselen as a Potent Inhibitor of DMT1-Mediated Iron Uptake. Chemistry & Biology 2006,13(9):965–972.CrossRef 25. Buckett PD, Wessling-Resnick M: Small molecule inhibitors of divalent metal transporter-1. Am J Physiol Gastrointest Liver Physiol 2009,296(4):G798–804.PubMedCrossRef ITF2357 datasheet 26. Turturro Francesco FEaWT: Hyperglycemia regulates thioredoxin-ROS activity through induction of thioredoxin-interacting

protein (TXNIP) in metastatic breast cancer-derived cells MDA-MB-231. BMC Cancer 2007,7(96):7. 27. Horonchik L, Wessling-Resnick M: The Small-Molecule Iron Transport Inhibitor Ferristatin/NSC306711 Promotes Degradation of the Transferrin Receptor. Chemistry & Biology 2008,15(7):647–653.CrossRef 28. Yang J, Goetz D, Li JY, Wang W, Mori K, Setlik D, Du T, Selleckchem GDC0449 Erdjument-Bromage H, Tempst Aurora Kinase inhibitor P, Strong R, et al.: An Iron Delivery Pathway Mediated by a Lipocalin. Molecular Cell 2002,10(5):1045–1056.PubMedCrossRef 29. Ludwiczek S, Theurl I, Muckenthaler MU, Jakab M, Mair SM, Theurl M, Kiss J,

Paulmichl M, Hentze MW, Ritter M, et al.: Ca2+ channel blockers reverse iron overload by a new mechanism via divalent metal transporter-1. Nat Med 2007,13(4):448–454.PubMedCrossRef 30. Liuzzi JP, Aydemir F, Nam H, Knutson MD, Cousins RJ: Zip14 (Slc39a14) mediates non-transferrin-bound iron uptake into cells. Proceedings of the National Academy of Sciences 2006,103(37):13612–13617.CrossRef 31. Pelicano H, Carney D, Huang P: ROS stress in cancer cells and therapeutic implications. Drug Resistance Updates 2004,7(2):97–110.PubMedCrossRef 32. Fruehauf JP, Meyskens FL: Reactive Oxygen Species: A Breath of Life or Death? Clinical Cancer Research 2007,13(3):789–794.PubMedCrossRef 33. Trachootham D, Lu W, Ogasawara MA, Valle NR-D, Huang P: Redox Regulation of Cell Survival. nearly Antioxidants & Redox Signaling 2008,10(8):1343–1374.CrossRef 34. Witte A-B, Anestål K, Jerremalm E, Ehrsson

H, Arnér ESJ: Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds. Free Radical Biology and Medicine 2005,39(5):696–703.PubMedCrossRef 35. Miyajima ANJ, Yoshioka K, Tachibana M, Tazaki H, Murai M: Role of reactive oxygen species in cis-dichlorodiammineplatinum-induced cytotoxicity on bladder cancer cells. Br J Cancer 1997,76(2):206–210.PubMedCrossRef 36. Hug H, Strand S, Grambihler A, Galle J, Hack V, Stremmel W, Krammer PH, Galle PR: Reactive Oxygen Intermediates Are Involved in the Induction of CD95 Ligand mRNA Expression by Cytostatic Drugs in Hepatoma Cells. Journal of Biological Chemistry 1997,272(45):28191–28193.PubMedCrossRef 37. Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, Lee CT, Lopaschuk GD, Puttagunta L, Bonnet S, et al.

Mar Ecol Prog Ser 257:69–76CrossRef Gantt E, Lipschultz CA (1974) Phycobilisomes of Porphyridium cruentum: pigment analysis. Biochemistry 13(14):2960–2966PubMedCrossRef Govindjee, Govindjee

R (1965) Two different manifestations of enhancement in the photosynthesis of Porphyridium cruentum in flashing monochromatic light. Photochem Photobiol 4:401–415 Govindjee, Krogmann D (2004) Discoveries in oxygenic photosynthesis (1727–2003): a perspective: selleck kinase inhibitor Dedicated to the memories of Martin Kamen (1920–2002) and William A. Arnold (1904–2001). Photosynth Res 80:15–57PubMedCrossRef Govindjee, Rabinowitch E (1960) Two forms of chlorophyll a in vivo with distinct photochemical functions. Science 132:159–160 Govindjee, Owens OvH, Hoch G (1963) A mass spectroscopic study of the Emerson enhancement effect. Biochim Biophys Acta 75:281–284PubMedCrossRef Govindjee R, Thomas JB, Rabinowitch E (1960) Second Emerson effect

in the Hill reaction of Chlorella cells with quinone as oxidant. Science 132:421PubMedCrossRef Halldal P (1968) Photosynthetic capacities and photosynthetic Vistusertib action spectra of endozoic algae of the massive coral Fava. Biol Bull 134:411–424CrossRef Haxo FT (1960) The wavelength dependence of photosynthesis and the role of accessory pigments. In: Allen MB (ed) Comparative biochemistry of photoreactive pigments. Academic Press, New York, pp 339–361 Haxo FT (1963) Some implications of recent studies on the role of accessory pigments to photosynthesis in submarine daylight. Methane monooxygenase In: Tuthill LD (ed) Proceedings 10th Pacific Science Assoc. Erismodegib Bishop Museum Press, Honolulu, HA, p 159 Haxo FT (2006) Remembering LR Blinks. In: A Tribute to Lawrence R. Blinks, Light, Ions, Algae, Amer Bot Soc July 31, Davis Ca. Botany 2006 abstract #38 in American Botanical Society web page under conferences Haxo F, Blinks LR (1946) Photosynthetic action spectra

in red algae. Amer J Bot 33:836–837 Haxo FT, Blinks LR (1950) Photosynthetic action spectra of marine algae. J Gen Physiol 33:389–422PubMedCrossRef Haxo FT, Fork DC (1959) Photosynthetically active accessory pigments of cryptomonads. Nature 184:1051–1052PubMedCrossRef Hill R, Bendall F (1960) Function of the cytochrome components in chloroplasts: a working hypothesis. Nature 186:136–137CrossRef Hodgkin AL (1951) The ionic basis of electrical activity. Biol Rev Camb Phil Soc 26:339–409CrossRef Hodgkin AL (1976) Chance and design in electrophysiology—Informal account of certain experiments on nerve carried out between 1932 and 1952. J Physiol 263:1–21PubMed Katchalsky A, Thorhaug A (1974) The effects of temperature and thermoosmosis on the membrane system of Valonia ventrocosa.. In: Nakamura K, Tsichiya Y (eds) Proc 7th Intnl Seaweed Symp. Tokyo, Japan, pp 1–12 Kok B, Jagendorf AT (1963) Preface In: Photosynthetic Mechanisms of Green Plants (B. Kok, Chairman; A.T.